PARIS, June 21, 2025 (BSS/AFP) - A new generation of weight-loss drugs has proven remarkably effective, hugely popular and ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

It has been found in a phase I study that patients taking Eli Lilly's investigational obesity drug eloralintide lost more ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

Research symposia focus on new combinations and medication formulations for both obesity and type 2 diabetes, as well as new ...

Controlling weight and cardiovascular risk factors is paramount in type 2 diabetes management; however, the definition and ...